Literature DB >> 23589850

LDL receptor and its family members serve as the cellular receptors for vesicular stomatitis virus.

Danit Finkelshtein1, Ariel Werman, Daniela Novick, Sara Barak, Menachem Rubinstein.   

Abstract

Vesicular stomatitis virus (VSV) exhibits a remarkably robust and pantropic infectivity, mediated by its coat protein, VSV-G. Using this property, recombinant forms of VSV and VSV-G-pseudotyped viral vectors are being developed for gene therapy, vaccination, and viral oncolysis and are extensively used for gene transduction in vivo and in vitro. The broad tropism of VSV suggests that it enters cells through a highly ubiquitous receptor, whose identity has so far remained elusive. Here we show that the LDL receptor (LDLR) serves as the major entry port of VSV and of VSV-G-pseudotyped lentiviral vectors in human and mouse cells, whereas other LDLR family members serve as alternative receptors. The widespread expression of LDLR family members accounts for the pantropism of VSV and for the broad applicability of VSV-G-pseudotyped viral vectors for gene transduction.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23589850      PMCID: PMC3645523          DOI: 10.1073/pnas.1214441110

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  54 in total

1.  An effective AIDS vaccine based on live attenuated vesicular stomatitis virus recombinants.

Authors:  N F Rose; P A Marx; A Luckay; D F Nixon; W J Moretto; S M Donahoe; D Montefiori; A Roberts; L Buonocore; J K Rose
Journal:  Cell       Date:  2001-09-07       Impact factor: 41.582

2.  RNAi screening reveals requirement for host cell secretory pathway in infection by diverse families of negative-strand RNA viruses.

Authors:  Debasis Panda; Anshuman Das; Phat X Dinh; Sakthivel Subramaniam; Debasis Nayak; Nicholas J Barrows; James L Pearson; Jesse Thompson; David L Kelly; Istvan Ladunga; Asit K Pattnaik
Journal:  Proc Natl Acad Sci U S A       Date:  2011-11-07       Impact factor: 11.205

3.  Genetically engineered vesicular stomatitis virus in gene therapy: application for treatment of malignant disease.

Authors:  Marilyn Fernandez; Mercedes Porosnicu; Dubravka Markovic; Glen N Barber
Journal:  J Virol       Date:  2002-01       Impact factor: 5.103

4.  Oncolytic activity of vesicular stomatitis virus is effective against tumors exhibiting aberrant p53, Ras, or myc function and involves the induction of apoptosis.

Authors:  S Balachandran; M Porosnicu; G N Barber
Journal:  J Virol       Date:  2001-04       Impact factor: 5.103

5.  Hepatitis C virus and other flaviviridae viruses enter cells via low density lipoprotein receptor.

Authors:  V Agnello; G Abel; M Elfahal; G B Knight; Q X Zhang
Journal:  Proc Natl Acad Sci U S A       Date:  1999-10-26       Impact factor: 11.205

6.  Targeting tumor vasculature with an oncolytic virus.

Authors:  Caroline J Breitbach; Naomi S De Silva; Theresa J Falls; Usaf Aladl; Laura Evgin; Jennifer Paterson; Yang Yang Sun; Dominic G Roy; Julia L Rintoul; Manijeh Daneshmand; Kelley Parato; Marianne M Stanford; Brian D Lichty; Aaron Fenster; David Kirn; Harold Atkins; John C Bell
Journal:  Mol Ther       Date:  2011-03-01       Impact factor: 11.454

7.  The epithelial-specific adaptor AP1B mediates post-endocytic recycling to the basolateral membrane.

Authors:  Yunbo Gan; Timothy E McGraw; Enrique Rodriguez-Boulan
Journal:  Nat Cell Biol       Date:  2002-08       Impact factor: 28.824

8.  Polybrene increases retrovirus gene transfer efficiency by enhancing receptor-independent virus adsorption on target cell membranes.

Authors:  Howard E Davis; Jeffrey R Morgan; Martin L Yarmush
Journal:  Biophys Chem       Date:  2002-06-19       Impact factor: 2.352

Review 9.  Current advances in retroviral gene therapy.

Authors:  Youngsuk Yi; Moon Jong Noh; Kwan Hee Lee
Journal:  Curr Gene Ther       Date:  2011-06       Impact factor: 4.391

10.  Broad antigenic coverage induced by vaccination with virus-based cDNA libraries cures established tumors.

Authors:  Timothy Kottke; Fiona Errington; Jose Pulido; Feorillo Galivo; Jill Thompson; Phonphimon Wongthida; Rosa Maria Diaz; Heung Chong; Elizabeth Ilett; John Chester; Hardev Pandha; Kevin Harrington; Peter Selby; Alan Melcher; Richard Vile
Journal:  Nat Med       Date:  2011-06-19       Impact factor: 53.440

View more
  203 in total

1.  Detection and Tracking of Dual-Labeled HIV Particles Using Wide-Field Live Cell Imaging to Follow Viral Core Integrity.

Authors:  João I Mamede; Thomas J Hope
Journal:  Methods Mol Biol       Date:  2016

Review 2.  Viral vector-based tools advance knowledge of basal ganglia anatomy and physiology.

Authors:  Rachel J Sizemore; Sonja Seeger-Armbruster; Stephanie M Hughes; Louise C Parr-Brownlie
Journal:  J Neurophysiol       Date:  2016-02-17       Impact factor: 2.714

3.  Wnt directs the endosomal flux of LDL-derived cholesterol and lipid droplet homeostasis.

Authors:  Cameron C Scott; Stefania Vossio; Fabrizio Vacca; Berend Snijder; Jorge Larios; Olivier Schaad; Nicolas Guex; Dmitry Kuznetsov; Olivier Martin; Marc Chambon; Gerardo Turcatti; Lucas Pelkmans; Jean Gruenberg
Journal:  EMBO Rep       Date:  2015-04-07       Impact factor: 8.807

Review 4.  Live virus vaccines based on a vesicular stomatitis virus (VSV) backbone: Standardized template with key considerations for a risk/benefit assessment.

Authors:  David K Clarke; R Michael Hendry; Vidisha Singh; John K Rose; Stephen J Seligman; Bettina Klug; Sonali Kochhar; Lisa Marie Mac; Baevin Carbery; Robert T Chen
Journal:  Vaccine       Date:  2016-07-06       Impact factor: 3.641

5.  Robust kinetics of an RNA virus: Transcription rates are set by genome levels.

Authors:  Collin Timm; Ankur Gupta; John Yin
Journal:  Biotechnol Bioeng       Date:  2015-05-20       Impact factor: 4.530

6.  Lassa-vesicular stomatitis chimeric virus safely destroys brain tumors.

Authors:  Guido Wollmann; Eugene Drokhlyansky; John N Davis; Connie Cepko; Anthony N van den Pol
Journal:  J Virol       Date:  2015-04-15       Impact factor: 5.103

Review 7.  Improving Molecular Therapy in the Kidney.

Authors:  Jeffrey D Rubin; Michael A Barry
Journal:  Mol Diagn Ther       Date:  2020-08       Impact factor: 4.074

8.  Ruxolitinib and Polycation Combination Treatment Overcomes Multiple Mechanisms of Resistance of Pancreatic Cancer Cells to Oncolytic Vesicular Stomatitis Virus.

Authors:  Sébastien A Felt; Gaith N Droby; Valery Z Grdzelishvili
Journal:  J Virol       Date:  2017-07-27       Impact factor: 5.103

Review 9.  The transformative potential of HSC gene therapy as a genetic medicine.

Authors:  Pervinder Sagoo; H Bobby Gaspar
Journal:  Gene Ther       Date:  2021-05-26       Impact factor: 5.250

Review 10.  Gene Therapy for Beta-Hemoglobinopathies: Milestones, New Therapies and Challenges.

Authors:  Valentina Ghiaccio; Maxwell Chappell; Stefano Rivella; Laura Breda
Journal:  Mol Diagn Ther       Date:  2019-04       Impact factor: 4.074

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.